Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aurinia Pharmaceuticals

7.84
+0.17502.28%
Volume:493.09K
Turnover:3.87M
Market Cap:1.08B
PE:195.88
High:7.91
Open:7.77
Low:7.75
Close:7.66
Loading ...

Aurinia: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring

TIPRANKS
·
07 Nov 2024

BRIEF-Aurinia Pharma Reports Q3 And Nine-Months 2024 Results, Announces Restructuring To Focus On Lupkynis And AUR200

Reuters
·
07 Nov 2024

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Business Wire
·
07 Nov 2024

Stock Track | Aurinia Pharmaceuticals Soars on Blowout Q3 Earnings Beat

Stock Track
·
07 Nov 2024

Aurinia Pharmaceuticals Q3 2024 Adj EPS $0.10 Beats $0.01 Estimate, Sales $67.80M Beat $57.69M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Aurinia Pharmaceuticals Q3 Operating Income USD 11.748 Million

Reuters
·
07 Nov 2024

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued Lupkynis® Growth and Aur200 Development

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Inc - to Reduce Workforce by Approximately 45% in Restructuring

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Inc - Expects Q4 Restructuring Charge of $15-$19 Mln

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Inc - Reiterates 2024 Net Product Revenue Guidance of $210-$220 Mln

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Q3 Pretax Profit USD 14.807 Million

THOMSON REUTERS
·
07 Nov 2024

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Business Wire
·
07 Nov 2024

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago

Simply Wall St.
·
02 Nov 2024

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Business Wire
·
31 Oct 2024

Aurinia Pharmaceuticals Inc expected to post earnings of 2 cents a share - Earnings Preview

Reuters
·
29 Oct 2024

Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024

TIPRANKS
·
11 Oct 2024

Aurinia Presents New Data Highlighting Real-World Utilization and Value of Lupkynis® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

THOMSON REUTERS
·
11 Oct 2024

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Business Wire
·
11 Oct 2024